Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261363 | 1.00 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4274607 | 1.00 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4323818 | 1.00 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4259736 | 1.00 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4264801 | 1.00 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4325773 | 0.85 | ADORA2A (0.63) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4261123 | 0.85 | ADORA2A (0.63) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4266821 | 0.85 | ADORA2A (0.63) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4259692 | 0.85 | ADORA2A (0.63) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL4274505 | 0.85 | ADORA2A (0.63) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | claimed |
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | claimed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | claimed |
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | ADORA2A 63/4885ADORA3 138/4885ADORA1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.